Rupatadine

It is a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Its chemical designation is 8-chloro-11-[1-(5-methyl-3-pyridinyl)methyl]piperidin-4-ylidene]-6, 11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridine fumarate. The empirical formula is C26H26CIN3.C4H4O4 and molecular weight is 532.04.

Indications

Seasonal and perennial allergic rhinitis, Bronchitis.

Dosage

The recommended dosage is 10mg (one tablet) once daily, with or without food.

Contra-Indications

It should not be administered in patients those show hypersensitivity to Rupatadine or any of the excipients.

Special Precautions

Rupatadine should be used with caution in old patients and in renal or hepatic insufficiency, and in children less than 12 years. Paediatrics: Neither the safety nor the efficacy of Rupatadine has been established in patients less then 12 years of age. Pregnancy and lactation : There is no clinical data available on the exposure of Rupatadine during pregnancy. Pregnant women should therefore not use Rupatadine, unless the potential benefit outweighs the potential risk for the infant. No information is available, whether Rupatadine is excreted in the mother’s milk. Therefore, it should not be used during lactation, unless the potential benefits for the mother justify the potential risk to the infant. Elderly : Rupatadine should be used with caution in elderly. No information is available that indicates the requirement of any dose adjustment in this population. Patients with renal or hepatic insufficiency : Use of Rupatadine is not recommended in patients with renal or hepatic insufficiency, as no relevant clinical data is available.

Drug Interactions

Potential interaction with CYP3A4 inhibitors like Ketoconazole or Erythromycin.